GlassScriptPhysician profile
John Ruckdeschel
NPI 1356380851
$1,535.45
in general payments reported to CMS, 2019-2025
22 companies · $76.47 in 2025
The $76.47 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $195 · 2021: $27.49 · 2025: $76.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $276.81 | 2019-2025 | Talvey |
| Ethicon INC. | $198.46 | 2019 | |
| Merck Sharp & Dohme LLC | $194.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.01 | 2019 | |
| Janssen Scientific Affairs, LLC | $123.68 | 2020 | |
| Tesaro, INC. | $121.74 | 2019 | |
| Genentech USA, INC. | $88.24 | 2019 | |
| Astellas Pharma US INC | $83.20 | 2019 | |
| Amgen INC. | $45.10 | 2019 | |
| Gilead Sciences, INC. | $37.78 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $36.58 | 2019 | |
| Pfizer INC. | $34.76 | 2019-2020 | |
| Lilly USA, LLC | $26.37 | 2019-2020 | |
| Daiichi Sankyo INC. | $18.42 | 2025 | Enhertu |
| Celgene Corporation | $18.13 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.89 | 2019 | |
| Seagen INC. | $15.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.33 | 2019 | |
| Kyowa Kirin, INC. | $13.99 | 2019 | |
| Becton, Dickinson and Company | $13.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.35 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ruckdeschel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.